LGVNLongeveron Inc.

Nasdaq longeveron.com


$ 1.97 $ -0.19 (-8.8 %)    

Friday, 06-Sep-2024 15:58:17 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 1.97
$ 1.96 x 100
-- x --
-- - --
$ 0.77 - $ 26.80
601,296
na
28.29M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-11-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-longeveron-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...

 longeveron-announces-type-c-meeting-with-us-fda-regarding-pathway-to-bla-for-lomecel-b-in-hypoplastic-left-heart-syndrome

On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA...

 maxim-group-maintains-buy-on-longeveron-lowers-price-target-to-6

Maxim Group analyst Michael Okunewitch maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $15 to...

 hc-wainwright--co-reiterates-buy-on-longeveron-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...

 longeveron-q2-2024-gaap-eps-183-up-from-267-yoy-sales-46800k-miss-52500k-estimate

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.83) per share. This is a 31.46 percent increase over losses of $(2.67...

 longeveron-has-been-granted-australian-patent-number-2017213812-titled-mesenchymal-stem-cells-as-vaccine-adjuvants-and-methods-for-using-the-same

https://ipsearch.ipaustralia.gov.au/patents/2017213812

 hc-wainwright--co-reiterates-buy-on-longeveron-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...

 why-is-alzheimers-focused-longeveron-stock-trading-higher-on-monday

Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's saf...

Core News & Articles
Market-Moving News for July 29th
07/29/2024 12:22:29

LGVN:  49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Di...

 hc-wainwright--co-maintains-buy-on-longeveron-lowers-price-target-to-10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target...

 longeveron-announced-study-results-from-clear-mind-phase-2a-clinical-trial-of-lomecel-b-in-mild-alzheimers-disease--study-meets-its-key-objectives-to-advance-data-supporting-favorable-benefitrisk-profile

- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for...

 why-longeveron-lgvn-shares-are-down-15

Longeveron shares are trading lower by 15.9% during Thursday's session. The company announced a $9.0 million registered dir...

 longeveron-enters-into-agreements-for-issuance-and-sale-of-22m-shares-of-class-a-common-stock-at-4025-per-share-in-registered-direct-offering

Concurrent Private Placement To Issue Unregistered Warrants For 2.2M Shares With $3.90 Exercise Price; Offering Expected To Clo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION